NewLimit
Backed by
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Group Lead, Immunology
Scientist, mRNA Downstream Purification
Scientist, mRNA Analytical Development
Senior/Research Associate, mRNA Engineering
Scientist- Delivery Sciences-targeted LNPs (tLNPs)
Scientist, Metabolism
Senior/Research Associate, Single Cell Technology
Senior Scientist / Scientist, In Vivo Pharmacology
Senior Manager, Lab Operations
Director / Senior Director, Clinical Operations
Talent Lead
